Abstract
Background: We described lifestyle changes one year after acute coronary syndrome (ACS) among patients in Arabian Gulf countries.
Methodology: Data of patients admitted to 29 hospitals in 4 countries with the diagnosis of ACS were analysed from Gulf citizens with ACS events (Gulf COAST) registry. A total of 3565 ACS patients recruited in the Gulf COAST registry had a one-year follow up available. There was a significant correlation between return to work and the age of patient (p < .001). At one-year post ACS, the majority were performing their usual activities (93%), but only 39% were exercising. Smoking cessation was successful in 60% of patients and most non-quitters tried or considered quitting (18 and 21% of the total population of smokers, respectively). Sexual activity was reported from 2290 male patients at one-year follow up. The majority reported performing sexual activity (66%) with no fear of sexual intercourse (57%).
Results and Conclusion: At one year after an ACS, the majority of our patients returned to their work, sexual activity and other usual activity. Clearly, improvement is needed when it comes to smoking cessation and exercise.
Keywords: Lifestyle, acute coronary syndrome, arabian gulf, middle east, registries, CRF.
Graphical Abstract
Current Vascular Pharmacology
Title:Lifestyle Changes among ACS Survivors in Arabian Gulf Countries (Gulf COAST Registry)
Volume: 16 Issue: 4
Author(s): F. Al-Roomi*, A. Khesroh, I. Al-Zakwani, S. Attur, W. Rashed and M. Zubaid
Affiliation:
- Department of Internal Medicine, Al-Amiri Hospital, Kuwait City,Kuwait
Keywords: Lifestyle, acute coronary syndrome, arabian gulf, middle east, registries, CRF.
Abstract: Background: We described lifestyle changes one year after acute coronary syndrome (ACS) among patients in Arabian Gulf countries.
Methodology: Data of patients admitted to 29 hospitals in 4 countries with the diagnosis of ACS were analysed from Gulf citizens with ACS events (Gulf COAST) registry. A total of 3565 ACS patients recruited in the Gulf COAST registry had a one-year follow up available. There was a significant correlation between return to work and the age of patient (p < .001). At one-year post ACS, the majority were performing their usual activities (93%), but only 39% were exercising. Smoking cessation was successful in 60% of patients and most non-quitters tried or considered quitting (18 and 21% of the total population of smokers, respectively). Sexual activity was reported from 2290 male patients at one-year follow up. The majority reported performing sexual activity (66%) with no fear of sexual intercourse (57%).
Results and Conclusion: At one year after an ACS, the majority of our patients returned to their work, sexual activity and other usual activity. Clearly, improvement is needed when it comes to smoking cessation and exercise.
Export Options
About this article
Cite this article as:
Al-Roomi F.*, Khesroh A., Al-Zakwani I., Attur S., Rashed W. and Zubaid M., Lifestyle Changes among ACS Survivors in Arabian Gulf Countries (Gulf COAST Registry), Current Vascular Pharmacology 2018; 16 (4) . https://dx.doi.org/10.2174/1570161115666170529090700
DOI https://dx.doi.org/10.2174/1570161115666170529090700 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design MiR-101 Attenuates Myocardial Infarction-induced Injury by Targeting DDIT4 to Regulate Autophagy
Current Neurovascular Research Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Relationship Between the Pharmacokinetics of Levosimendan and Its Effects on Cardiovascular System
Current Drug Metabolism Stem Cells and Cardiac Disease: Where are We Going?
Current Stem Cell Research & Therapy Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Mesenchymal Stem Cells Derived from Wharton's Jelly of the Umbilical Cord: Biological Properties and Emerging Clinical Applications
Current Stem Cell Research & Therapy An update on Anti-inflammatory Compounds: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Obstructive Sleep Apnea and Type 2 Diabetes: Dual Interaction
Current Respiratory Medicine Reviews Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Pleiotropic Effects of ARB in Diabetes Mellitus
Current Vascular Pharmacology Subclinical Thyroid Dysfunction and Cardiovascular Outcomes among Prospective Cohort Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Sulfonamide Group in Matrix Metalloproteinase Inhibitors
Current Medicinal Chemistry Expression and Function of Anti-Inflammatory Interleukins: The Other Side of the Vascular Response to Injury
Current Vascular Pharmacology Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Immune Endocrinological Evaluation in Patients with Severe Vascular Acquired Brain Injuries: Therapeutical Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus- Host Disease After Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy